1. Search Result
Search Result
Results for "

chronic idiopathic constipation (CC)

" in MedChemExpress (MCE) Product Catalog:
Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15790

    A 3309; AZD 7806

    Apical Sodium-Dependent Bile Acid Transporter Metabolic Disease Inflammation/Immunology Cancer
    Elobixibat (A 3309; AZD 7806) is an orally active, bile acid transporter (IBAT) inhibitor with IC50 values ??of 0.53 nM (human IBAT), 0.13 nM (mouse IBAT), and 5.8 nM (canine IBAT). Elobixibat can lower LDL cholesterol, increase serum GLP-1, promote colonic motility, and has the potential to treat metabolic syndrome. Elobixibat can be used in the study of chronic functional constipation (CIC), dyslipidemia, non-alcoholic hepatitis, and liver tumors in the elderly .
    Elobixibat
  • HY-15790R

    A 3309 (Standard); AZD 7806 (Standard)

    Apical Sodium-Dependent Bile Acid Transporter Metabolic Disease Inflammation/Immunology Cancer
    Elobixibat (Standard) is the analytical standard of Elobixibat (HY-15790). This product is intended for research and analytical applications. Elobixibat (A 3309; AZD 7806) is orally active, bile acid transporter (IBAT) inhibitor with IC50 values ??of 0.53 nM (human IBAT), 0.13 nM (mouse IBAT), and 5.8 nM (canine IBAT). Elobixibat can lower LDL cholesterol, increase serum GLP-1, promote colonic motility, and has the potential to treat metabolic syndrome. Elobixibat can be used in the study of chronic functional constipation (CIC), dyslipidemia, non-alcoholic hepatitis, and liver tumors in the elderly .
    Elobixibat (Standard)
  • HY-15790H

    (S)-A 3309; (S)-AZD 7806

    Apical Sodium-Dependent Bile Acid Transporter TNF Receptor Interleukin Related Metabolic Disease Inflammation/Immunology
    (S)-Elobixibat is the S enantiomer of Elobixibat (HY-15790). (S)-Elobixibat is an orally effective Apical Sodium-Dependent Bile (IBAT) inhibitor. (S)-Elobixibat decreases LDL cholesterol, increases serum GLP-1, promotes colon motility, and has the potential to treat metabolic syndrome. (S)-Elobixibat can be used to study constipation, dyslipidemia, non-alcoholic hepatitis, and liver tumors .
    (S)-Elobixibat